Evaluating miRNA Sequencing and Integrative Proteomics for Identifying Plasma miRNAs as Potential Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70444 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Mai Mehanna und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U…. Hauptthemen laut MEDLINE: Interferon beta-1a, MicroRNAs, Proteomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We used miRNA sequencing to identify candidate plasma pharmacodynamic (PD) biomarkers of interferon beta‐1a (IFNβ‐1a) biologics and explored miRNA‐mRNA targeted protein relationships and networks to support identified miRNA candidates. Plasma samples from 36 healthy subjects from a placebo‐controlled randomized single‐dose clinical study with IFNβ‐1a and pegIFNβ‐1a were used. Mature miRNAs were measured using an in‐house miRNA‐seq workflow at baseline, at 9 timepoints over 6 days in the IFNβ‐1a group ( n = 11 [30 μg]), and at 11 timepoints over 13 days in the pegIFNβ‐1a group ( n = 11 [125 μg]) and placebo‐specific groups ( n = 6 each). A miRNA was only considered expressed if it had a read count ≥ 10 in more than 50% of the samples across all treatment groups. Linear mixed‐effects models ( lmer ) regressing miRNA changes with treatment, time, and their interaction were used to identify differentially expressed miRNAs, which were further prioritized based on the magnitude of response and biological relevance using in silico predicted miRNA‐protein targets and regulatory network analyses. Ten and 13 miRNAs were impacted by IFNβ‐1a and pegIFNβ‐1a, respectively ( lmer FDR‐corrected p value < 0.1), compared to placebo, of which miR‐223‐3p and miR‐21‐5p were prioritized as candidate PD biomarkers for both products. Systems‐level analysis of integrated proteomics data highlighted miRNAs' protein targets for both miR‐223‐3p and miR‐21‐5p that were linked to previously reported top proteomic response proteins and predicted regulatory networks including the IFN beta node. Using miRNA sequencing and linking candidates to predicted target proteins and regulatory networks, results suggest miR‐223‐3p and miR‐21‐5p as potential PD biomarkers of IFNβ‐1a biologics for further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Therapeutic Biologics Program, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID-Profile: Mai Mehanna, Lakshmi Manasa Chekka, Deepti P Samarth, Isaac Raplee, Catherine Sullenberger, Erica Decker, Sarah J Schrieber, Yow-Ming Wang, Jeffry Florian, Paula L Hyland
Zitieren
APA
Mehanna, M., Chekka, L. M., Rosenzweig, B. A., Samarth, D. P., Mohamed, E. G., Raplee, I., Sullenberger, C., Decker, E., Schrieber, S. J., Wang, Y. M., Florian, J., & Hyland, P. L. (2025). Evaluating miRNA Sequencing and Integrative Proteomics for Identifying Plasma miRNAs as Potential Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics. Clinical and Translational Science. https://doi.org/10.1111/cts.70444
Vancouver
Mehanna M, Chekka LM, Rosenzweig BA, Samarth DP, Mohamed EG, Raplee I, et al. Evaluating miRNA Sequencing and Integrative Proteomics for Identifying Plasma miRNAs as Potential Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics. Clinical and Translational Science. 2025. doi:10.1111/cts.70444
BibTeX
@article{Mehanna2025,
author = {Mehanna, Mai and Chekka, Lakshmi Manasa and Rosenzweig, Barry A and Samarth, Deepti P and Mohamed, Esraa G and Raplee, Isaac and Sullenberger, Catherine and Decker, Erica and Schrieber, Sarah J and Wang, Yow-Ming and Florian, Jeffry and Hyland, Paula L},
title = {Evaluating miRNA Sequencing and Integrative Proteomics for Identifying Plasma miRNAs as Potential Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70444}
}
EUVIMED